Swiss biotech ObsEva has announced a corporate restructuring and layoffs following a notice from the FDA that the company’s new drug application (NDA) for its lead candidate linzagolix for uterine fibroids has deficiencies that are keeping the agency from advancing its review.
Source: Drug Industry Daily